FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hashim Mir						2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI]									k all app	tionship of Reporting Pe all applicable) Director Officer (give title below) Chief Scientific		rson(s) to Is 10% O Other (/ner	
(Last) (First) (Middle) C/O RANI THERAPEUTICS LLC						3. Date of Earliest Transaction (Month/Day/Year) 09/09/2021									belov			below)		
2051 RINGWOOD AVE.						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	SE CA	Λ 9	5131			X Form filed by One I Form filed by More Person									-					
(City)	(City) (State) (Zip)													F 6130	JII					
		Table	I - No	n-Deriva	ative S	Secu	rities	Acq	juired,	Dis	posed of	, or E	3ene	ficiall	y Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Exec if an	cution [y	eemed ution Date, th/Day/Year)		ction Instr.	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Secur Benet		cially l Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										v	Amount	(A) (D)	or P	Price	Transa	ction(s) 3 and 4)			(1130.4)	
Class A Common Stock 09/09/2					2021	021 (1)			A		117,600	I	A :	\$0.00		17,600		D		
		Tal							,		osed of, convertib			•	Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, //Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		ite	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Str.	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Following Reported Transactio (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Numl of Share							

Explanation of Responses:

1. The shares subject to the restricted stock unit grant vest as follows: 50% of the RSUs shall vest on September 9, 2022, and 50% shall vest on September 9, 2023.

Remarks:

/s/ Josh Seidenfeld, Attorneyin-Fact for Mir Hashim

09/13/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.